Quarterly report pursuant to Section 13 or 15(d)

Other Income / (Expense) (Tables)

v3.23.3
Other Income / (Expense) (Tables)
3 Months Ended
Sep. 30, 2023
Notes Tables  
Schedule of the components of other income (expense)

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):

Quarter Ended

September 30, 

    

2023

    

2022

Interest expense

$

(4,893)

$

(3,790)

Interest income

890

433

Gain (loss) on investment(1)

283

49,769

Gain (loss) on equity method investment

(2,290)

Other non-operating income (expense), net

 

(294)

 

987

Total other income (expense)

$

(6,304)

$

47,399

(1) Primarily due to a $0.3 million gain on the sale of our exchange traded investment grade bond funds during the quarter ended September 30, 2023 compared to a $37.2 million gain on the sale of our ChemoCentryx investment and a $11.7 million gain on the sale of Eminence in the quarter ended September 30, 2022.